These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20088937)

  • 1. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
    Büller HR; Gallus AS; Pillion G; Prins MH; Raskob GE;
    Lancet; 2012 Jan; 379(9811):123-9. PubMed ID: 22130488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idraparinux and idrabiotaparinux.
    Harenberg J
    Expert Rev Clin Pharmacol; 2010 Jan; 3(1):9-16. PubMed ID: 22111528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
    Veyrat-Follet C; Vivier N; Trellu M; Dubruc C; Sanderink GJ
    J Thromb Haemost; 2009 Apr; 7(4):559-65. PubMed ID: 19187079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.
    Song Y; Li X; Pavithra S; Li D
    PLoS One; 2013; 8(11):e78972. PubMed ID: 24278113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
    Harenberg J
    Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2017 Jan; 73(1):15-28. PubMed ID: 27742998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
    Savi P; Herault JP; Duchaussoy P; Millet L; Schaeffer P; Petitou M; Bono F; Herbert JM
    J Thromb Haemost; 2008 Oct; 6(10):1697-706. PubMed ID: 18647228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
    Prandoni P; Tormene D; Perlati M; Brandolin B; Spiezia L
    Expert Opin Investig Drugs; 2008 May; 17(5):773-7. PubMed ID: 18447601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
    Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
    J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.
    van Doormaal FF; Cohen AT; Davidson BL; Decousus H; Gallus AS; Gent M; Piovella F; Prins MH; Raskob GE; Büller HR
    Thromb Haemost; 2010 Jul; 104(1):86-91. PubMed ID: 20508907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.
    Vahtera A; Valkonen M; Huhtala H; Pettilä V; Kuitunen A
    Thromb Res; 2017 Oct; 158():71-75. PubMed ID: 28846877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idrabiotaparinux treatment for venous thromboembolism.
    Eikelboom JW; Weitz JI
    Lancet; 2012 Jan; 379(9811):96-8. PubMed ID: 22127297
    [No Abstract]   [Full Text] [Related]  

  • 20. Idraparinux versus standard therapy for venous thromboembolic disease.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.